15 april 2025 Sweden
CEO Ulf Hannelius and board member Mark Atkinson are interviewed by Direkt Studios about the strategic positioning of Diamyd Medical, including the therapeutic platform, current and future indications, commercial opportunities, and upcoming milestones.
The broadcast is produced by Direkt Studios, an independent part of the editorial team at Nyhetsbyrån Direkt.
|
10 april 2025 USA
Diamyd Medical’s CEO Ulf Hannelius discusses genetic insights into clinical progress - the evolution of Diamyd Medical's antigen-specific immunotherapy.
The Sugar Science is an interactive digital platform founded to curate the scientific conversation among type 1 diabetes (T1D) researchers.
|
9 april 2025 Sweden
Diamyd Medical´s vd Ulf Hannelius presenterar bolagets Delårsrapport 2 och nuvarande status i bolaget. Delårsrapporten publicerades den 9 april 2025. Producerat i samarbete med G&W Fondkomission.
|
8 april 2025 USA
This article features insights from three key speakers invited by Diamyd Medical for the Women’s Health event hosted by The Life Science Bridge on March 27th, 2025.
The event explored challenges and advancements in women’s health, particularly in relation to autoimmune conditions like Type 1 Diabetes.
Comments and interviews include Ginger Vieira, author and Type 1 Diabetes patient; Dr. Emily Sims, associate professor of pediatrics, and member of the Diamyd Medical Scientific Advisory Board, and Dr. Karin Rosén, MD, PhD, and Board Member of Diamyd Medical. Read the article here Presentations from the event are available here: Bridging the Gap 2025 - Dr. Karin Rosén, Dr. Emily K. Sims, and Ginger Vieira Bridging the Gap 2025 - Dr. Ulf Hannelius, President & CEO of Diamyd Medical
|
1 april 2025 USA
CEO Ulf Hannelius spoke at Bridging the Gap, presented by Life Science Bridge. This year’s focus was women’s health, with autoimmune diseases like diabetes on the agenda. Diamyd Medical was one of the event sponsors. Diamyd Medical’s ongoing Phase 3 trial includes clinics in both the U.S. and Europe, but the company is focusing its commercial efforts on the U.S. market. “It’s the biggest market, and a single regulatory and insurance landscape makes it more efficient to launch there first,” Hannelius said. “If you need to choose, you choose the U.S.” Read the article here
Silicon Valley Nordic Beat summarizes CEO Ulf Hannelius speech at the annual event presented by Life Science Bridge—a joint initiative between the regional chambers of commerce in San Diego, San Francisco/Silicon Valley, Minnesota, and New England.
|